

Dactinomycin




NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc

ATC codes: L01DA01

ICD11 code: 2D9Z

Indication	Unspecified malignant neoplasms of ill-defined or unspecified sites
INN	Dactinomycin
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 500 µg in vial powder for injection
EML status history	First added in 1984 (TRS 722) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . 
Wikipedia	Dactinomycin 
DrugBank	Dactinomycin 

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of bleomycin was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for bleomycin for more information.

